Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01520207 · ClinicalTrials.gov registry record · Phase 2
Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01520207 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 52 participants.
The verdict
NCT01520207, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Kidney failure can result from a variety of conditions and can be temporary or permanent. Hemodialysis is available as a replacement treatment to perform the work that the kidneys normally do. However, the dialysis procedure can be associated with rapid changes in the composition of the blood - this may lead to changes in blood pressure and in turn reduced blood supply to important parts of the body. We aim to investigate if giving a medicine (called mannitol) during dialysis may be able to reduce the frequency of these low blood pressure events.
Interventions
- DRUG 0.9% saline
- DRUG Mannitol (20%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-05 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01520207
The ClinicalTrials.gov registry entry for NCT01520207 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.9% saline is the first listed.
NCT01520207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01520207 about?
NCT01520207 is a clinical study titled "Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension". Kidney failure can result from a variety of conditions and can be temporary or permanent. Hemodialysis is available as a replacement treatment to perform the work that the kidneys normally do. However, the dialysis procedure can be associated with rapid changes in the composition of the blood - this...
What is the current status of trial NCT01520207?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2012-05. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01520207?
The interventions under investigation include: 0.9% saline (DRUG), Mannitol (20%) (DRUG).
Who is sponsoring clinical trial NCT01520207?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.